BioHarvest Sciences Inc. (BHST) AI Stock Analysis

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States across two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. Its operations include the research, development, manufacturing, marketing, and sale of science-based nutraceutical solutions, such as dietary supplements and functional food and beverages, as well as pharmaceutical and cosmeceutical solutions. It also provides contract development and manufacturing operation services, offers VINIA red grape cell dietary supplements, and maintains a strategic collaboration with Tate & Lyle plc for developing plant-based sweetener molecules.

BioHarvest Sciences delivered a five-year revenue CAGR of 144.4% between FY2020 and FY2025. Annual revenue expanded from $2.1M in FY2021 to $5.5M in FY2022, $12.7M in FY2023, $25.2M in FY2024, and $34.5M in FY2025, representing 37.0% growth in the latest fiscal year. Gross margin improved from 31.9% in FY2021 to 59.3% in FY2025. Operating margin rose from -403.9% in FY2021 to -16.2% in FY2025, while net income finished at -$11.1M. For the trailing twelve months ended June 30, 2026, revenue was $35.5M with a profit margin of -31.2%, and quarterly revenue growth was 3.8% year-over-year.

As of June 30, 2026, BioHarvest Sciences held $16.2M in cash and short-term investments against total debt of $17.5M, leaving net debt of $1.3M. Total assets stood at $44.6M and shareholders' equity was $19.8M, yielding a current ratio of 2.24 and a debt-to-equity ratio of 0.89. In FY2025, operating cash flow was -$7.2M and capital expenditures were $2.4M, resulting in free cash flow of -$9.6M. Additionally, the company increased its share count by 82.4% over five years.

At a last close of $1.85 on October 16, 2026, BioHarvest Sciences had a market capitalization of $41.9M and an enterprise value of $35.7M. The stock trades at a price-to-sales multiple of 1.2x and a forward P/E of 153.8x, compared to the median of its US-listed Consumer Defensive peers of 0.7x and 14.3x, respectively. Its enterprise value-to-revenue ratio is 1.0x. Over the past year, the stock fell 83.9%, compared to a 16.8% gain for the S&P 500. The shares traded 45.9% below their 200-day average.

BioHarvest Sciences carries 3 Strong Buy ratings and 1 Buy rating from analysts, with zero Hold, Sell, or Strong Sell recommendations. The mean price target is $10.50, which sits 467.6% above the last close of $1.85. For the fiscal year ending December 31, 2026, analysts estimate revenue of $37.4M and EPS of -$0.53. For the next fiscal year, 4 analysts project revenue of $49.6M and EPS of -$0.34. The company has beaten EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of BioHarvest Sciences Inc. (BHST). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BHST income statement, BHST balance sheet, BHST key metrics, BHST analyst forecast, BHST chart. See the BHST stock overview for the latest quote and news.